Empagliflozin as add-on to metformin in people with Type 2 diabetes

Diabetic Medicine

Volumn 32, Issue 12, 2015, Pages 1555-1567

  Merker, Ludwig ^a   Haring H U ^b   Christiansen, A V ^c   Roux, F ^d   Salsali, A ^e   Kim, G ^c   Meinicke, T ^c   Woerle, H J ^c   Broedl, U C ^c  

^a Diabetes und Nierenzentrum   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d BOEHRINGER INGELHEIM   (France)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; URIC ACID; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; ARTICLE; BACKACHE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; BODY MASS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DOSE RESPONSE; DRUG RESISTANCE; EXERCISE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERWEIGHT; RANDOMIZED CONTROLLED TRIAL;

AGED; BENZHYDRYL COMPOUNDS; BODY MASS INDEX; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EXERCISE; FEMALE; GLUCOSIDES; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MEMBRANE TRANSPORT MODULATORS; METFORMIN; MIDDLE AGED; OVERWEIGHT; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84983201802     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12814     Document Type: Article

References (24)

1. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
2. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014; 104: 297-322.
3. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 613-621.
4. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-219.
5. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 369-384.
6. Haering HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37: 1650-1659.
7. Haering HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404.
8. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16: 147-158.
9. Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ et al. Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes. Diabetes Care 2014; 37: 1815-1823.
10. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700.
11. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
12. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
13. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 479-484.
14. Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014; 30: 1109-1119.
15. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 984-993.
16. Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013; 36: 4015-4021.
17. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013; 15: 1154-1160.
18. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124: 499-508.
19. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275.
20. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597.
21. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43.
22. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care 2015; 38: 355-364.
23. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S, for the Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014; 16: 124-136.
24. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-451.